Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection

Author:

Takemori Toshitada123,Sugimoto-Ishige Akiko12,Nishitsuji Hironori4,Futamura Yushi5,Harada Michishige1,Kimura-Someya Tomomi6,Matsumoto Takehisa6,Honma Teruki7,Tanaka Miho1,Yaguchi Masami1,Isono Kyoichi8,Koseki Haruhiko9,Osada Hiroyuki5,Miki Daiki1011,Saito Takashi1,Tanaka Takashi2,Fukami Takehiro12,Goto Toshio12,Shirouzu Mikako6,Shimotohno Kunitada13,Chayama Kazuaki111415ORCID

Affiliation:

1. Drug Discovery Antibody Platform Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

2. Laboratory for Inflammatory Regulation, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

3. Department of Clinical Laboratory, Tokyo Shinagawa Hospital, Tokyo, Japan

4. Department of Virology and Parasitology, Fujita Health University School of Medicine, Toyoake, Japan

5. Chemical Biology Research Group, RIKEN Center for Sustainable Resource Science, Wako, Japan

6. Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan

7. Drug Discovery Computational Chemistry Platform Unit, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan

8. Laboratory Animal Center, Wakayama Medical University, Wakayama, Japan

9. Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

10. Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima City, Japan

11. Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima City, Japan

12. RIKEN Program for Drug Discovery and Medical Technology Platforms, RIKEN Cluster for Science, Technology and Innovation Hub, Yokohama, Japan

13. Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan

14. Collaborative Research Laboratory of Medical Innovation, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

15. RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

Abstract

A number of entry inhibitors are being developed to enhance the treatment of HBV patients with oral nucleoside/nucleotide analogues (NA). To amplify the effectiveness of NA therapy, several efforts have been made to develop therapeutic MAbs with neutralizing activity against HBs antigens.

Funder

Japan Agency for Medical Research and Development

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3